Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 20/20 | 0.77 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.77 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.77 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.77 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.77 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pf-04217903 SCHEMBL1178576 | 0.90 | MET (0.92) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL2570505 | 0.90 | MET (0.80) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL16366038 | 0.88 | MET (0.80) | METCYP2C9PDE3BPDE3APDE10A | |
| Pf-04217903 SCHEMBL29355971 | 0.87 | MET (1.00) | METCYP2C9PDE3BPDE3APDE10A | |
| Pf-04217903 SCHEMBL93550 | 0.87 | MET (1.00) | METCYP2C9PDE3BPDE3APDE10A | |
| Pf-04217903 SCHEMBL29394198 | 0.87 | MET (1.00) | METCYP2C9PDE3BPDE3APDE10A | |
| Pf-04217903 SCHEMBL1178807 | 0.86 | MET (0.98) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL2571583 | 0.86 | MET (0.74) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL29528188 | 0.86 | MET (0.74) | METCYP2C9PDE3BPDE3APDE10A | |
| SCHEMBL2572767 | 0.85 | MET (0.84) | METCYP2C9PDE3BPDE3APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110039856-A1 | POLYMORPHS OF A C-MET/HGFR INHIBITOR | PFIZER INC. | 2011-02-17 | — | — | US | claimed |
| EP-2227473-A2 | POLYMORPHS OF A C-MET/HGFR INHIBITOR | Pfizer Inc. (US) | 2010-09-15 | — | — | EP | claimed |
| WO-2009068955-A2 | POLYMORPHS OF A C-MET/HGFR INHIBITOR | PFIZER INC. (US) | 2009-06-04 | — | — | WO | claimed |
| US-20110039856-A1 | POLYMORPHS OF A C-MET/HGFR INHIBITOR | PFIZER INC. | 2011-02-17 | — | — | US | disclosed |
| EP-2227473-A2 | POLYMORPHS OF A C-MET/HGFR INHIBITOR | Pfizer Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| WO-2009068955-A2 | POLYMORPHS OF A C-MET/HGFR INHIBITOR | PFIZER INC. (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110039856-A1 | POLYMORPHS OF A C-MET/HGFR INHIBITOR | MET, HGF, KRAS | MET 1/4885CYP2C9 2267/4885PDE3B 4134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.